These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9467685)

  • 21. Development of anti-TNF therapy for rheumatoid arthritis.
    Feldmann M
    Nat Rev Immunol; 2002 May; 2(5):364-71. PubMed ID: 12033742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for arthritis.
    Traister RS; Hirsch R
    Mod Rheumatol; 2008; 18(1):2-14. PubMed ID: 18176779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Gene therapy in rheumatoid arthritis--an already feasible therapeutic principle?].
    Kalden JR; Geiler T; Herrmann M; Bertling W
    Z Rheumatol; 1998 Jun; 57(3):139-46. PubMed ID: 9702834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic targets for rheumatoid arthritis: Progress and promises.
    Alghasham A; Rasheed Z
    Autoimmunity; 2014 Mar; 47(2):77-94. PubMed ID: 24437572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients?
    van de Loo FA; Smeets RL; van den Berg WB
    Arthritis Res Ther; 2004; 6(5):183-96. PubMed ID: 15380032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease-Regulated Gene Therapy with Anti-Inflammatory Interleukin-10 Under the Control of the CXCL10 Promoter for the Treatment of Rheumatoid Arthritis.
    Broeren MG; de Vries M; Bennink MB; Arntz OJ; Blom AB; Koenders MI; van Lent PL; van der Kraan PM; van den Berg WB; van de Loo FA
    Hum Gene Ther; 2016 Mar; 27(3):244-54. PubMed ID: 26711533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects of immunotherapy for rheumatoid arthritis.
    t Hart BA; Otten HG
    Pharm World Sci; 1995 Nov; 17(6):178-85. PubMed ID: 8597773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery: a model for the therapy of rheumatoid arthritis.
    Woods AM; Thompson SJ; Wooley PH; Panayi G; Klavinskis LS
    Arthritis Rheum; 2005 Dec; 52(12):3761-71. PubMed ID: 16329091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapeutic targets in rheumatoid arthritis.
    Jorgensen C
    Joint Bone Spine; 2000; 67(4):277-82. PubMed ID: 10963074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Experimental therapy of rheumatoid arthritis with cytokine antagonists].
    Manger B
    Z Rheumatol; 1995; 54(2):105-9. PubMed ID: 7793156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene transfer as a future therapy for rheumatoid arthritis.
    Müller-Ladner U; Pap T; Gay RE; Gay S
    Expert Opin Biol Ther; 2003 Jul; 3(4):587-98. PubMed ID: 12831364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathways to gene therapy in rheumatoid arthritis.
    Evans CH; Robbins PD
    Curr Opin Rheumatol; 1996 May; 8(3):230-4. PubMed ID: 8796983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy.
    Xu WD; Zhang M; Zhang YJ; Ye DQ
    Hum Immunol; 2013 Sep; 74(9):1057-60. PubMed ID: 23800433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technology insight: gene transfer and the design of novel treatments for rheumatoid arthritis.
    Moritz F; Distler O; Ospelt C; Gay RE; Gay S
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):153-62. PubMed ID: 16932675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging cytokine targets in rheumatoid arthritis.
    Asquith DL; McInnes IB
    Curr Opin Rheumatol; 2007 May; 19(3):246-51. PubMed ID: 17414950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy for rheumatoid arthritis: current status and future prospects.
    Fabre S; Apparailly F
    BioDrugs; 2011 Dec; 25(6):381-91. PubMed ID: 22050340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
    van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
    Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy for rheumatoid arthritis.
    Gouze JN; Ghivizzani SC; Gouze E; Palmer GD; Betz OB; Robbins PD; Evans CH; Herndon JH
    Hand Surg; 2001 Dec; 6(2):211-9. PubMed ID: 11901469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for rheumatoid arthritis.
    Bessis N; Doucet C; Cottard V; Douar AM; Firat H; Jorgensen C; Mezzina M; Boissier MC
    J Gene Med; 2002; 4(6):581-91. PubMed ID: 12439850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenoviral-mediated gene transfer to the synovial tissue.
    Goossens PH; Huizinga TW
    Clin Exp Rheumatol; 2002; 20(3):415-9. PubMed ID: 12102483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.